ID | 1058 |
Name of the vaccine | Tripacel |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Combination |
Nucleic acid content | DNA |
Age | 2 months to 6 years |
Description of the vaccine | Diphtheria, tetanus toxoids and acellular pertussis vaccine adsorbed. |
Name of the manufacturer | Sanofi Pasteur Limited |
Name of the manufacturing country | Canada |
Year of manufacture | 1998 |
Clinical Phase status | Approved |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | Absolute vaccine efficacy of 85% against pertussis disease. |
Vaccine formulation | White to off-white suspension for injection |
Dosage | Four dose series with 3 doses at gap of 2 months, followed by a booster dose 6 to 12 months after the third dose. |
Mechanism of action | Contains five pertussis antigens which are related to protection against pertussis. |
Route of administration | Intramuscular |
Indications | Immunization against diphtheria, tetanus and pertussis. |
Export | Marketing Authorisation Holder: Sanofi Pasteur Ltd, Bangkok, Thailand |
Approval | Thailand FDA |
Adjuvant | Aluminium phosphate |
Repurposing | Also for diphtheria and tetanus. |
Side effects of vaccine | Drowsiness, injection site tenderness, swelling, redness, fever, irritability, decreased feeding. |
Post vaccination | NA |
Dose type | Combination doses |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NA |
Reference | https://www.fda.moph.go.th/sites/drug/Summary/2C_18_41_N.pdf |
Other name | NA |
Additional Links | http://www.guildlink.com.au/gc/ws/sw/pi.cfm?product=swptripa20320
|